Immunocore Holdings plc
IMCR
Cena:
$ 28.83
-1.17 (-3.90%)
Valuace
100
Růst
70
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
IMMUNOCORE ANNOUNCES R&D LEADERSHIP EVOLUTION
30-01-2026
IMMUNOCORE ANNOUNCES R&D LEADERSHIP EVOLUTION DR. DAVID BERMAN WILL DEPART THE COMPANY DR. MOHAMMED ...
Více zde
IMMUNOCORE ANNOUNCES 2026 STRATEGIC PRIORITIES AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
09-01-2026
IMMUNOCORE ANNOUNCES 2026 STRATEGIC PRIORITIES AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE REAC...
Více zde
IMMUNOCORE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
10-11-2025
(OXFORDSHIRE, ENGLAND & CONSHOHOCKEN, PENN. & GAITHERSBURG, MD....
Více zde
IMMUNOCORE PRESENTS PHASE 1 DATA FOR HEPATITIS B CANDIDATE AT AASLD'S THE LIVER MEETING
07-11-2025
SINGLE ASCENDING DOSE DATA SHOW IMC-I109V HAS MANAGEABLE SAFETY PROFILE AND ANTIVIRAL ACTIVITY IMC-I...
Více zde
IMMUNOCORE REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
06-11-2025
IMMUNOCORE REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE KIMMTRAK ® (TEBEN...
Více zde
IMMUNOCORE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
04-09-2025
IMMUNOCORE TO PRESENT AT UPCOMING INVESTOR CONFERENCES (OXFORDSHIRE, ENGLAND & CONSHOHOCKEN, PENN. &...
Více zde
IMMUNOCORE REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
07-08-2025
KIMMTRAK ® (TEBENTAFUSP-TEBN) NET REVENUES OF $98.0 MILLION IN Q2 2025, GROWING BY 30% YEAR-OVER-YE...
Více zde
IMMUNOCORE TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CALL ON AUGUST 7, 2025
31-07-2025
(OXFORDSHIRE, ENGLAND & CONSHOHOCKEN, PENN. & GAITHERSBURG, MD....
Více zde
ER-KIM ANNOUNCES EXCLUSIVE AGREEMENT WITH IMMUNOCORE TO DISTRIBUTE KIMMTRAK IN TURKEY, AND THE MENA, CAUCASUS AND CIS REGIONS
30-06-2025
RIYADH, SAUDI ARABIA AND ISTANBUL AND OXFORDSHIRE, UNITED KINGDOM, JUNE 30, 2025 (GLOBE NEWSWIRE) --...
Více zde
IMMUNOCORE TO PRESENT AT THE 2025 JEFFERIES GLOBAL HEALTHCARE CONFERENCE
02-06-2025
(OXFORDSHIRE, ENGLAND & CONSHOHOCKEN, PENN. & GAITHERSBURG, MD....
Více zde
IMMUNOCORE REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
07-05-2025
IMMUNOCORE REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE KIMMTRAK ® (TEBEN...
Více zde
IMMUNOCORE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
02-04-2025
IMMUNOCORE TO PRESENT AT UPCOMING INVESTOR CONFERENCES (OXFORDSHIRE, ENGLAND & CONSHOHOCKEN, PENN. &...
Více zde
IMMUNOCORE PRESENTS INITIAL MULTIPLE ASCENDING DOSE DATA FOR HIV FUNCTIONAL CURE CANDIDATE IN AN ORAL PRESENTATION AT CROI 2025
10-03-2025
IMMUNOCORE PRESENTS INITIAL MULTIPLE ASCENDING DOSE DATA FOR HIV FUNCTIONAL CURE CANDIDATE IN AN ORA...
Více zde
IMMUNOCORE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
03-03-2025
(OXFORDSHIRE, ENGLAND & CONSHOHOCKEN, PENN. & GAITHERSBURG, MD., US, 03 MARCH 2025) IMMUNOCORE HOLD...
Více zde
IMMUNOCORE REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
26-02-2025
KIMMTRAK (TEBENTAFUSP) Q4 NET SALES OF $84.1 MILLION AND $310.0 MILLION FOR FULL YEAR 2024; CONTINUE...
Více zde
IMMUNOCORE TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HOST CALL ON FEBRUARY 26, 2025
19-02-2025
(OXFORDSHIRE, ENGLAND & CONSHOHOCKEN, PENN. & GAITHERSBURG, MD., US, 19 FEBRUARY 2025) IMMUNOCORE H...
Více zde
IMMUNOCORE ANNOUNCES STRATEGIC PRIORITIES AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
10-01-2025
REACHING MORE MUM PATIENTS GLOBALLY WITH KIMMTRAK (TEBENTAFUSP) IN 2025 THROUGH ADDITIONAL LAUNCHES ...
Více zde
IMMUNOCORE TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
06-01-2025
IMMUNOCORE TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (OXFORDSHIRE, ENGLAND & C...
Více zde
IMMUNOCORE APPOINTS TRAVIS COY, PREVIOUSLY A NON-EXECUTIVE DIRECTOR, AS ITS EVP, CHIEF FINANCIAL OFFICER AND HEAD OF CORPORATE DEVELOPMENT
02-01-2025
IMMUNOCORE APPOINTS TRAVIS COY, PREVIOUSLY A NON-EXECUTIVE DIRECTOR, AS ITS EVP, CHIEF FINANCIAL OFF...
Více zde
IMMUNOCORE ANNOUNCES FIRST PATIENT DOSED IN THE PHASE 1 TRIAL OF IMC-P115C, A HALF-LIFE EXTENDED (HLE) IMMTAC CANDIDATE IN PATIENTS WITH TUMORS THAT EXPRESS PRAME
23-12-2024
IMMUNOCORE ANNOUNCES FIRST PATIENT DOSED IN THE PHASE 1 TRIAL OF IMC-P115C, A HALF-LIFE EXTENDED (HL...
Více zde
IMMUNOCORE ANNOUNCES REIMBURSEMENT AGREEMENT IN ENGLAND FOR KIMMTRAK▼ FOR THE TREATMENT OF HLA-A*02:01-POSITIVE ADULTS WITH UNRESECTABLE OR METASTATIC UVEAL MELANOMA
03-12-2024
IMMUNOCORE ANNOUNCES REIMBURSEMENT AGREEMENT IN ENGLAND FOR KIMMTRAK▼ FOR THE TREATMENT OF HLA-A*0...
Více zde
IMMUNOCORE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
08-11-2024
(OXFORDSHIRE, ENGLAND & CONSHOHOCKEN, PENN. & GAITHERSBURG, MD., US, 8 NOVEMBER 2024) IMMUNOCORE HOL...
Více zde
IMMUNOCORE REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
06-11-2024
IMMUNOCORE REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE KIMMTRAK ® (TEBEN...
Více zde
IMMUNOCORE PRESENTS PHASE 1 DATA OF BRENETAFUSP, AN IMMTAC BISPECIFIC TARGETING PRAME, IN PATIENTS WITH OVARIAN CANCER
14-09-2024
IMMUNOCORE PRESENTS PHASE 1 DATA OF BRENETAFUSP, AN IMMTAC BISPECIFIC TARGETING PRAME, IN PATIENTS W...
Více zde
IMMUNOCORE TO PRESENT AT THE 2024 CANTOR GLOBAL HEALTHCARE CONFERENCE
12-09-2024
IMMUNOCORE TO PRESENT AT THE 2024 CANTOR GLOBAL HEALTHCARE CONFERENCE (OXFORDSHIRE, ENGLAND & CONSHO...
Více zde
IMMUNOCORE PRESENTS KIMMTRAK CLINICAL DATA DEMONSTRATING THAT PATIENTS WITH STABLE DISEASE AND CONFIRMED TUMOR REDUCTION HAVE SIMILAR CLINICAL OUTCOMES TO PATIENTS WITH PARTIAL RESPONSE
01-06-2024
IMMUNOCORE PRESENTS KIMMTRAK CLINICAL DATA DEMONSTRATING THAT PATIENTS WITH STABLE DISEASE AND CONFI...
Více zde
IMMUNOCORE REPORTS UPDATED PHASE 1 DATA OF BRENETAFUSP (IMC-F106C), AN IMMTAC BISPECIFIC TARGETING PRAME, IN IMMUNE CHECKPOINT PRE-TREATED CUTANEOUS MELANOMA PATIENTS AT ASCO 2024
31-05-2024
IMMUNOCORE REPORTS UPDATED PHASE 1 DATA OF BRENETAFUSP (IMC-F106C), AN IMMTAC BISPECIFIC TARGETING P...
Více zde
IMMUNOCORE TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE
30-05-2024
IMMUNOCORE TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE (OXFORDSHIRE, ENGLAND & CONSHOHO...
Více zde
IMMUNOCORE CONVERTS PHASE 2/3 TEBE-AM CLINICAL TRIAL INTO REGISTRATIONAL PHASE 3 TRIAL EVALUATING KIMMTRAK FOR PREVIOUSLY TREATED ADVANCED CUTANEOUS MELANOMA
29-05-2024
IMMUNOCORE CONVERTS PHASE 2/3 TEBE-AM CLINICAL TRIAL INTO REGISTRATIONAL PHASE 3 TRIAL EVALUATING KI...
Více zde
IMMUNOCORE REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
08-05-2024
IMMUNOCORE REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE KIMMTRAK ® (TEBEN...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2026-01-30 00:00:00 | 8-K |  | Stáhnout |
| 2026-01-09 00:00:00 | 8-K | | Stáhnout |
| 2025-11-28 00:00:00 | 8-K | | Stáhnout |
| 2025-11-06 00:00:00 | 8-K | | Stáhnout |
| 2025-11-06 00:00:00 | 10-Q | | Stáhnout |
| 2025-08-07 01:00:00 | 8-K | | Stáhnout |
| 2025-08-07 01:00:00 | 10-Q | | Stáhnout |
| 2025-08-07 00:00:00 | 8-K | | Stáhnout |
| 2025-08-07 00:00:00 | 10-Q | | Stáhnout |
| 2025-05-15 01:00:00 | 8-K | | Stáhnout |
| 2025-05-15 00:00:00 | 8-K | | Stáhnout |
| 2025-05-07 01:00:00 | 8-K | | Stáhnout |
| 2025-05-07 01:00:00 | 10-Q | | Stáhnout |
| 2025-05-07 00:00:00 | 8-K | | Stáhnout |
| 2025-05-07 00:00:00 | 10-Q | | Stáhnout |
| 2025-03-17 00:00:00 | 8-K | | Stáhnout |
| 2025-03-16 23:00:00 | 8-K | | Stáhnout |
| 2025-03-10 00:00:00 | 8-K | | Stáhnout |
| 2025-03-09 23:00:00 | 8-K | | Stáhnout |
| 2025-02-26 00:00:00 | 8-K | | Stáhnout |
| 2025-02-26 00:00:00 | 10-K | | Stáhnout |
| 2025-02-25 23:00:00 | 8-K | | Stáhnout |
| 2025-02-25 23:00:00 | 10-K | | Stáhnout |
| 2025-01-10 00:00:00 | 8-K | | Stáhnout |
| 2025-01-09 23:00:00 | 8-K | | Stáhnout |
| 2025-01-02 00:00:00 | 8-K | | Stáhnout |
| 2025-01-01 23:00:00 | 8-K | | Stáhnout |
| 2024-11-08 00:00:00 | 8-K | | Stáhnout |
| 2024-11-07 23:00:00 | 8-K | | Stáhnout |
| 2024-11-06 00:00:00 | 8-K | | Stáhnout |
| 2024-11-06 00:00:00 | 10-Q | | Stáhnout |
| 2024-11-05 23:00:00 | 8-K | | Stáhnout |
| 2024-11-05 23:00:00 | 10-Q | | Stáhnout |
| 2024-09-16 01:00:00 | 8-K | | Stáhnout |
| 2024-09-16 00:00:00 | 8-K | | Stáhnout |
| 2024-08-29 01:00:00 | 8-K | | Stáhnout |
| 2024-08-29 00:00:00 | 8-K | | Stáhnout |
| 2024-08-08 01:00:00 | 8-K | | Stáhnout |
| 2024-08-08 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-08 00:00:00 | 8-K | | Stáhnout |
| 2024-08-08 00:00:00 | 10-Q | | Stáhnout |
| 2024-05-31 01:00:00 | 8-K | | Stáhnout |
| 2024-05-31 00:00:00 | 8-K | | Stáhnout |
| 2024-05-30 01:00:00 | 8-K | | Stáhnout |
| 2024-05-30 00:00:00 | 8-K | | Stáhnout |
| 2024-05-28 01:00:00 | 8-K | | Stáhnout |
| 2024-05-28 00:00:00 | 8-K | | Stáhnout |
| 2024-05-23 01:00:00 | 8-K | | Stáhnout |
| 2024-05-23 00:00:00 | 8-K | | Stáhnout |
| 2024-05-08 01:00:00 | 8-K | | Stáhnout |
| 2024-05-08 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-08 00:00:00 | 8-K | | Stáhnout |
| 2024-05-08 00:00:00 | 10-Q | | Stáhnout |
| 2024-04-05 01:00:00 | 8-K | | Stáhnout |
| 2024-04-05 00:00:00 | 8-K | | Stáhnout |
| 2024-02-28 00:00:00 | 8-K | | Stáhnout |
| 2024-02-28 00:00:00 | 10-K | | Stáhnout |
| 2024-02-27 23:00:00 | 8-K | | Stáhnout |
| 2024-02-27 23:00:00 | 10-K | | Stáhnout |
| 2024-02-02 00:00:00 | 8-K | | Stáhnout |
| 2024-02-01 23:00:00 | 8-K | | Stáhnout |
| 2024-01-29 00:00:00 | 8-K | | Stáhnout |
| 2024-01-28 23:00:00 | 8-K | | Stáhnout |
| 2024-01-05 00:00:00 | 8-K | | Stáhnout |
| 2024-01-04 23:00:00 | 8-K | | Stáhnout |
| 2024-01-02 00:00:00 | 8-K | | Stáhnout |
| 2024-01-01 23:00:00 | 8-K | | Stáhnout |
